OncoMatch/Clinical Trials/NCT05331105

HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Is NCT05331105 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies HL-085 for neurofibromatosis 1.

Phase 2RecruitingShanghai Kechow Pharma, Inc.NCT05331105Data as of May 2026

Treatment: HL-085 — This is a Multi-center, Open-label, Single-arm Phase II Study to Evaluate the Efficacy and Safety of HL-085 in the treatment of Adult Participants with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas(PN)

Check if I qualify

Extracted eligibility criteria

Biomarker criteria

Required: NF1 mutation

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: MEK inhibitor

Prior treatment with MEK 1/2 inhibitors

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify